What determines the cost-effectiveness of diabetes screening?

Diabetologia

Volumn 49, Issue 7, 2006, Pages 1536-1544

  Glumer C ^a,b,c   Yuyun, M ^a   Griffin, S ^a   Farewell, D ^d   Spiegelhalter, D ^e   Kinmonth, A L ^f   Wareham, N J ^a  

^a MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^b STENO DIABETES CENTER   (Denmark)

^c Research Centre for Prevention and Health   (Denmark)

^d LANCASTER UNIVERSITY   (United Kingdom)

^e MRC BIOSTATISTICS UNIT   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cost effectiveness; Decision modelling; Diabetes; Screening; Uncertainty

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE MODEL; FEMALE; HEALTH CARE; HEALTH CARE POLICY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RISK; RISK REDUCTION; SCREENING; SENSITIVITY ANALYSIS; SIMULATION;

ADULT; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; MONTE CARLO METHOD; SENSITIVITY AND SPECIFICITY;

EID: 33744932399     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0248-x     Document Type: Article

References (26)

1. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431
2. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621
3. Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A (2003) Screening for Type 2 diabetes - should it be now? Diabet Med 20:175-181
4. Wareham NJ, Griffin SJ (2001) Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ 322:986-988
5. Hofer TP, Vijan S, Hayward RA (2000) Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 16:822-833
6. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M (2004) Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 140:689-699
7. Briggs AH (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479-500
8. Lawrence JM, Bennett P, Young A, Robinson AM (2001) Screening for diabetes in general practice: cross sectional population study. BMJ 323:548-551
9. Williams DR, Wareham NJ, Brown DC et al (1995) Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabetic Med 12:30-35
10. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 101:671-679
11. Huang ES, Meigs JB, Singer DE (2001) The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633-642
12. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BHR, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24:S6-S11
13. Joint Formulary Committee (2002) British National Formulary. British Medical Association, and Royal Pharmaceutical Society of Great Britain, London
14. Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V et al (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 352:837-853
15. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847
16. Glumer C, Jorgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a danish population: the inter99 study. Diabetes Care 26:2335-2340
17. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). Eur J Cardiovasc Prev Rehabil 10:377-386
18. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. 1999. World Health Organization, Geneva 1999. WHO/NCD/NCS/99.2
19. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention (1998) The cost-effectiveness of screening for type 2 diabetes. JAMA 280:1757-1763
20. Chen TH-H, Yen MF, Tung TH (2001) A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. Diabetes Res Clin Pract 54:37-42
21. Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735-744
22. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393
23. Type 2-diabetes i almen praksis, en evidensbaseret vejledning. 2004. Dansk Selskab for Almen Medicin
24. American Diabetes Association (2006) Standards of medical care in diabetes - 2006. Diabetes Care 29:S4-S42
25. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264-3272
26. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86